Taliglucerase alfa, sold under the brand name Elelyso among others, is a biopharmaceutical medication developed by Protalix and Pfizer.
[7][2] The US FDA Supplemental New Drug Application (sNDA) for pediatric use was granted approved in August 2014.
[8] In Israel, the Israeli Ministry of Health granted approval in September 2012.
[9] In Brazil, the Brazilian Health Surveillance Agency (ANVISA) granted approval in March 2013.
[citation needed] For 2016, Elelyso was ranked third for pharmaceuticals with the highest cost-per-patient, with an average cost of $483,242 per year.